SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 -- Organizational restructuring to focus resources on ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

THIO combined with Libtayo shows a 38% ORR in advanced NSCLC resistant to checkpoint inhibitors, surpassing standard therapies. The phase 2 THIO-101 trial reports a disease control rate of 85% in ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

The antibody is currently undergoing a phase 1/2 trial as a monotherapy and in combination with Regeneron’s PD-1 inhibitor Libtayo in patients with resistance to PD-1 inhibitors. That study is ...

Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio third quarter 2024 financial results conference call ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Analysing the top 10 tech company logos, we can understand the art and science behind creating visual identities that stand out from the crowd. This article dives into the nuances of visual identity, ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of 20.2 months versus 15.9 months. The PERLA trial showed consistent OS ...

As we delve into this collection of notable alcohol logos, we will uncover the strategic thinking and design principles behind them. Learn more here! A logo is the face of a brand, encapsulating its ...

Patients with metastatic non-small cell lung cancer, even those with brain metastases, experienced improved longer-term clinical outcomes while on the Opdivo/Yervoy combination compared with those ...